Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 17/20 | 0.47 |
| ▸ | BRAF | P15056 | 17/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714564 | 0.91 | KIT (0.49) | KITBRAFBRD4CREBBPNOTUM | |
| SCHEMBL13714592 | 0.90 | KIT (0.50) | KITBRAF | |
| SCHEMBL13714601 | 0.90 | KIT (0.48) | KITBRAFBRD4CREBBPNOTUM | |
| SCHEMBL13714619 | 0.89 | KIT (0.49) | KITBRAFBRD4CREBBP | |
| SCHEMBL13714621 | 0.89 | KIT (0.47) | KITBRAFBRD4CREBBPNOTUM | |
| SCHEMBL13714533 | 0.89 | KIT (0.47) | KITBRAFBRD4CREBBPNOTUM | |
| SCHEMBL5178265 | 0.88 | KIT (0.47) | KITBRAFBRD4CREBBP | |
| SCHEMBL3866092 | 0.86 | KIT (0.50) | KITBRAF | |
| SCHEMBL13714590 | 0.86 | KIT (0.48) | KITBRAFBRD4CREBBPNOTUM | |
| SCHEMBL13714532 | 0.86 | KIT (0.48) | KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | claimed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | KIT 83/4885BRAF 495/4885BRD4 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.